Page 54 - Read Online

Reyngold et al. Hepatoma Res 2018;4:49 I http://dx.doi.org/10.20517/2394-5079.2018.84 Page 9 of 10

REFERENCES
1. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong
TS, Das P, Crane CH. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic
cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016;34:219-26.
2. Austin-Seymour MM, Chen GT, Castro JR, Saunders WM, Pitluck S, Woodruff KH, Kessler M. Dose volume histogram analysis of liver
radiation tolerance. Int J Radiat Oncol Biol Phys 1986;12:31-5.
3. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD.
The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992;23:781-8.
4. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, Lawrence TS. Escalated focal liver radiation and
concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18:2210-8.
5. Cheng JC, Wu JK, Huang CM, Huang DY, Cheng SH, Lin YM, Jian JJ, Yang PS, Chuang VP, Huang AT. Radiation-induced liver disease
after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 2002;63:41-5.
6. Cheng JC, Wu JK, Lee PC, Liu HS, Jian JJ, Lin YM, Sung JL, Jan GJ. Biologic susceptibility of hepatocellular carcinoma patients treated
with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004;60:1502-9.
7. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, Jiang GL. Radiation-induced liver disease in
three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat
Oncol Biol Phys 2006;65:426-34.
8. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, Benito A, Dominguez I, D’Avola D, Herrero JI,
Quiroga J, Prieto J, Sangro B. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013;57:1078-87.
9. Cheng JC, Wu JK, Huang CM, Liu HS, Huang DY, Cheng SH, Tsai SY, Jian JJ, Lin YM, Cheng TI, Horng CF, Huang AT. Radiation-
induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and
implication. Int J Radiat Oncol Biol Phys 2002;54:156-62.
10. Cao Y, Pan C, Balter JM, Platt JF, Francis IR, Knol JA, Normolle D, Ben-Josef E, Ten Haken RK, Lawrence TS. Liver function after
irradiation based on computed tomographic portal vein perfusion imaging. Int J Radiat Oncol Biol Phys 2008;70:154-60.
11. Cao Y, Wang H, Johnson TD, Pan C, Hussain H, Balter JM, Normolle D, Ben-Josef E, Ten Haken RK, Lawrence TS, Feng M. Prediction of
liver function by using magnetic resonance-based portal venous perfusion imaging. Int J Radiat Oncol Biol Phys 2013;85:258-63.
12. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing
proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-46.
13. Normolle D, Pan C, Ben-Josef E, Lawrence T. Adaptive trial of personalized radiotherapy for intrahepatic cancer. Per Med 2010;7:197-204.
14. Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, Parikh ND, Welling TH, Normolle D, Ten Haken RK, Lawrence
TS. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial.
JAMA Oncol 2018;4:40-7.
15. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann
Surg 2000;232:777-85.
16. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal
vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg
2004;240:1037-49; discussion 1049-51.
17. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol
2006;12:7561-7.
18. Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K. Prospective trial of combined
transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with
unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-9.
19. Chen SC, Lian SL, Chang WY. The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. Cancer
Chemother Pharmacol 1994;33 Suppl:S124-7.
20. Yamada K, Soejima T, Sugimoto K, Mayahara H, Izaki K, Sasaki R, Maruta T, Matsumoto S, Hirota S, Sugimura K. Pilot study of local
radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2001;31:147-52.
21. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF,
Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R,
Slotman BJ, Smit EF, Roth JA. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled
analysis of two randomised trials. Lancet Oncol 2015;16:630-7.
22. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R. Stereotactic body radiation therapy for
early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-82.
23. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar
LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006;45:848-55.
24. Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT. Predictors of toxicity associated with stereotactic body radiation
therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys 2015;91:986-94.
25. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M,
Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J
Clin Oncol 2013;31:1631-9.
26. Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, Abdulrahman R, Timmerman R. Four-dimensional computed
tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and
liver. Int J Radiat Oncol Biol Phys 2008;70:1571-8.